By reducing the burden of excess weight, cardiovascular and renal morbidity, and overall mortality, these novel therapies could significantly improve health outcomes and reduce disability among individuals with diabetes who are currently reliant on insulin—particularly in the case of GLP-1 receptor agonists. This evidence concerns the gene INS and diabetes mellitus.